Exploring the Susceptibility to Multiple Primary Tumors in Patients with Differentiated Thyroid Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: ( = 32) and without ( = 135) MPT compared to healthy subjects ( < 0
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] The results of this study suggest a role of the relative telomere length in predicting MPT development in DTC patients. Our results contribute to increasing the knowledge of the genetic mechanisms underlying MPT development in DTC patients, considering relative telomere length as a possible prognostic marker.
[PURPOSE] It was demonstrated that differentiated thyroid cancer (DTC) patients may develop multiple primary tumors (MPT) during follow-up.
- OR 0.466
APA
Valerio L, Cantara S, et al. (2024). Exploring the Susceptibility to Multiple Primary Tumors in Patients with Differentiated Thyroid Cancer.. Diagnostics (Basel, Switzerland), 14(12). https://doi.org/10.3390/diagnostics14121210
MLA
Valerio L, et al.. "Exploring the Susceptibility to Multiple Primary Tumors in Patients with Differentiated Thyroid Cancer.." Diagnostics (Basel, Switzerland), vol. 14, no. 12, 2024.
PMID
38928626
Abstract
[PURPOSE] It was demonstrated that differentiated thyroid cancer (DTC) patients may develop multiple primary tumors (MPT) during follow-up. Many studies showed an association between reduced telomere length and cancer phenotype; in particular, the short telomeres were associated with the development of a primary tumor. However, the role of altered telomere length in MPT development has not yet been demonstrated. The aim of this study was to evaluate the possible correlation between a short telomere length in blood leukocytes and the risk of developing MPT in DTC patients.
[PATIENTS AND METHODS] We retrospectively evaluated 167 DTC patients followed up for a median of 13.6 years. Our control group was represented by 105 healthy subjects without any thyroid disease or present or past history of tumors. Our study groups, age-matched, were evaluated for the relative telomere length measured in leukocytes of peripheral venous blood.
[RESULTS] The relative telomere length (RTL) was significantly different in healthy subjects compared to the total group of differentiated thyroid cancer patients [ < 0.0001]. Shorter telomeres length was observed in DTC patients with ( = 32) and without ( = 135) MPT compared to healthy subjects ( < 0.0001 and = 0.0002, respectively). At multivariate analysis, the parameters independently associated with the presence of MPT were RTL [OR: 0.466 (0.226-0.817), = 0.018] and the familial DTC [OR: 2.949 (1.142-8.466), = 0.032].
[CONCLUSIONS] The results of this study suggest a role of the relative telomere length in predicting MPT development in DTC patients. Our results contribute to increasing the knowledge of the genetic mechanisms underlying MPT development in DTC patients, considering relative telomere length as a possible prognostic marker.
[PATIENTS AND METHODS] We retrospectively evaluated 167 DTC patients followed up for a median of 13.6 years. Our control group was represented by 105 healthy subjects without any thyroid disease or present or past history of tumors. Our study groups, age-matched, were evaluated for the relative telomere length measured in leukocytes of peripheral venous blood.
[RESULTS] The relative telomere length (RTL) was significantly different in healthy subjects compared to the total group of differentiated thyroid cancer patients [ < 0.0001]. Shorter telomeres length was observed in DTC patients with ( = 32) and without ( = 135) MPT compared to healthy subjects ( < 0.0001 and = 0.0002, respectively). At multivariate analysis, the parameters independently associated with the presence of MPT were RTL [OR: 0.466 (0.226-0.817), = 0.018] and the familial DTC [OR: 2.949 (1.142-8.466), = 0.032].
[CONCLUSIONS] The results of this study suggest a role of the relative telomere length in predicting MPT development in DTC patients. Our results contribute to increasing the knowledge of the genetic mechanisms underlying MPT development in DTC patients, considering relative telomere length as a possible prognostic marker.
같은 제1저자의 인용 많은 논문 (5)
- Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.
- Radioiodine therapy in the different stages of differentiated thyroid cancer.
- Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test.
- Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination.
- Dynamic Risk Stratification Integrated with ATA Risk System for Predicting Long-Term Outcome in Papillary Thyroid Cancer.